Management of borderline tumors of the ovary: state of the art.

Abstract:

:Evidence published during several decades has shown that there is a group of epithelial ovarian tumors having histological and biological features between those of clearly benign and frankly malignant tumors. In 1963, FIGO accepted an intermediate group of ovarian carcinomas of low malignant potential. In 1973, WHO adopted the term borderline malignancies to describe these tumors. Borderline tumors represent approximately 10% to 15% of all epithelial ovarian malignancies. There are considerable discrepancies in the reported incidence of ovarian tumors of borderline malignancies. Some centers do not recognize tumors of this type and include them among invasive cancers. The prognosis for patients with borderline tumors is generally considered to be excellent. Although the standard treatment for older patients is abdominal hysterectomy and bilateral salpingo-oophorectomy, many young patients who have not completed childbearing can be safely treated with unilateral salpingo-oophorectomy coupled with comprehensive surgical staging, thereby preserving fertility potential. Even ovarian cystectomy has been reported, but the recurrence rate in the ovary approximates 15%. Many experts strongly believe that surgery is the only effective treatment for borderline tumors. Others routinely use postoperative chemotherapy for at least some subsets of patients with peritoneal implants. Currently, insufficient information is available to make a definitive statement regarding the efficacy of postoperative therapy. Nevertheless, clinicians are faced with the difficult task of making treatment recommendations to anxious patients. In the past, extensive application of automated methods for analytical cytology has resulted in large quantities of data on ploidy abnormalities in different types of human cancers. The main purpose has been to obtain additional parameters for the characterization of various types of malignancy to give more precise information on their biological behavior. Data from the Norwegian Radium Hospital showed that the majority of borderline tumors have DNA diploid tumors and good prognosis, DNA aneuploidy indicates high risk. Several other investigators have shown the same results on DNA ploidy as a predictor of recurrence and survival, but a few others have shown conflicting results. Early studies suggest that p53 mutation does not appear to play a role in the pathogenesis of these tumors. Studies on other molecular markers have not yet uncovered a reliable predictor of biologic behavior. However, it is hoped that future studies of genetics and molecular biology of these tumors will lead to useful laboratory tests.

journal_name

Semin Oncol

journal_title

Seminars in oncology

authors

Tropé C,Kaern J

subject

Has Abstract

pub_date

1998-06-01 00:00:00

pages

372-80

issue

3

eissn

0093-7754

issn

1532-8708

journal_volume

25

pub_type

杂志文章,评审
  • The alpha interferons: clinical overview.

    abstract::The clinical development of the recombinant alpha interferons has provided a prototype for the clinical development of biological compounds. With over 5,000 patients now treated with these compounds, some general principles have emerged that have wider implications for phase I-II strategies for testing other biologica...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,评审

    doi:

    authors: Spiegel RJ

    更新日期:1987-06-01 00:00:00

  • Early studies of etoposide phosphate, a water-soluble prodrug.

    abstract::Etoposide phosphate (Etopophos; Bristol-Myers Squibb Company, Princeton, NJ) is a water-soluble prodrug of etoposide that is converted in vivo by endogenous phosphatases to the active drug etoposide. This conversion process is efficient and not saturable in humans at doses between 50 and 1,600 mg/m2. The resultant eto...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Budman DR

    更新日期:1996-12-01 00:00:00

  • Pharmacogenetics in esophageal cancer.

    abstract::The current oncology practice of treating cancer with aggressive doses of radiation and chemotherapy is potentially disastrous, as response and side effects vary depending on several factors including pharmacogenetics. This study is the first to evaluate esophageal cancer treatment with a pharmacogenetic paradigm and ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2005.04.031

    authors: Wu X,Lu C,Chiang SS,Ajani JA

    更新日期:2005-12-01 00:00:00

  • Use of preclinical models to assess the therapeutic potential of new drug candidates for bladder cancer.

    abstract::The purpose of this review is to demonstrate a successful use of preclinical models of bladder cancer to confirm the therapeutic potential of new promising drug candidates. The bladder has long been thought to be an ideal target for investigating therapies. When developing a new antineoplastic pharmaceutical agent, th...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2012.08.006

    authors: Amit D,Gofrit ON,Matouk I,Birman T,Hochberg A

    更新日期:2012-10-01 00:00:00

  • The half century of clinical trials of the National Surgical Adjuvant Breast And Bowel Project.

    abstract::The supplanting of radical mastectomy by simple mastectomy and then by lumpectomy plus radiation, the use of adjuvant therapy to alter the natural course of breast and colorectal cancer, the use of tamoxifen for the prevention of breast cancer, and the dramatic improvement in survival demonstrated with the use of the ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2008.07.005

    authors: Wickerham DL,O'Connell MJ,Costantino JP,Cronin WM,Paik S,Geyer CE Jr,Ganz PA,Petrelli N,Mamounas EP,Julian TB,Wolmark N

    更新日期:2008-10-01 00:00:00

  • Phase II trial evaluating triplet chemotherapy using gemcitabine, paclitaxel, and carboplatin in the treatment of patients with advanced non-small cell lung cancer.

    abstract::The purpose of this study was to evaluate the combination of gemcitabine, paclitaxel, and carboplatin in patients with advanced non-small cell lung cancer. Previously untreated patients with stage IIIB or IV non-small cell lung cancer were enrolled into this trial. Sixty-nine patients from the phase II portion and eig...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:

    authors: Burris HA 3rd,Hainsworth JD,Erland JB,Morrissey LH,Kalman LA,Hon JK,Scullin DC Jr,Smith SW,Greco FA

    更新日期:2000-02-01 00:00:00

  • Paclitaxel in the treatment of esophageal cancer.

    abstract::Since its introduction, paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated significant antitumor activity in epidermoid carcinomas and adenocarcinomas originating in the esophagus. Paclitaxel is the most active single agent available to treat metastatic esophageal cancer. Combinations of ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Weiner LM

    更新日期:1999-02-01 00:00:00

  • Phase I dose-escalation trial of paclitaxel and ifosfamide in patients with advanced non-small cell lung cancer.

    abstract::This phase I dose-escalation study was undertaken to determine the maximum tolerated doses of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and ifosfamide that could be administered without growth factors to previously untreated patients with non-small cell lung cancer. Forty patients with advanced n...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Shepherd FA,Latreille J,Paul K,Eisenhauer E

    更新日期:1996-12-01 00:00:00

  • Quality of life considerations in patients with advanced lung cancer.

    abstract::Quality of life (QOL) is an important consideration in the treatment of patients with advanced lung cancer because treatment is largely palliative. Moreover, QOL predicts survival in non-small cell lung cancer, and there is increasing acceptance by clinicians and regulatory authorities of symptoms and QOL as primary o...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2004.10.004

    authors: Cella D

    更新日期:2004-12-01 00:00:00

  • Infections in allogeneic bone marrow transplant recipients.

    abstract::Remarkable strides have been made in the management of infectious complications after bone marrow transplantation. Improved understanding of patterns of infection, the introduction of new antimicrobials, the advent of cytokines to enhance immune recovery, the development of better strategies to control graft-versus-ho...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Wingard JR

    更新日期:1993-10-01 00:00:00

  • Beyond detectable minimal residual disease in chronic lymphocytic leukemia.

    abstract::Lymphoproliferative disorders are characterized by the abnormal accumulation of aberrant lymphocytes, which frequently interfere with the processes associated with immunologic response and hematopoiesis. Chronic lymphocytic leukemia (CLL) has traditionally been considered indolent, with a prolonged clinical course. Ho...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2006.01.026

    authors: Hillmen P

    更新日期:2006-04-01 00:00:00

  • Paclitaxel (Taxol): phase I/II trial comparing 1-hour infusion schedules.

    abstract::This phase I/II study was done to evaluate the safety and feasibility of two schedules of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) administered by 1-hour infusion in the outpatient setting. Fifty-six patients with advanced, refractory malignancies received one of two paclitaxel schedules by rand...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Greco FA,Hainsworth JD

    更新日期:1994-10-01 00:00:00

  • Symptom control in advanced cancer.

    abstract::Most important is the physician's attitude, energy, and skill focused toward helping the patient through the difficulties in the last weeks of life. Many causes of nausea, dyspnea, and other troublesome symptoms can be effectively treated, and pharmacologic palliation is nearly always possible. A multidisciplinary tea...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Storey P

    更新日期:1994-12-01 00:00:00

  • Recent developments in breast cancer therapy.

    abstract::Over the past three decades conceptual approaches to breast cancer have led to improvements in locoregional therapy and early diagnosis. Systematic screening programs with mammography reduce disease-specific mortality by 25% to 30%, while many patients with early breast cancer receive optimal breast-conserving treatme...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Hortobagyi GN,Hung MC,Buzdar AU

    更新日期:1999-08-01 00:00:00

  • Should radiotherapy be standard therapy for brain tumors in the elderly? Cons.

    abstract::Elderly patients with malignant gliomas present unique treatment challenges. Data are limited on the efficacy of various treatment modalities for high-grade gliomas in the elderly patient population, particularly for patients over 70 years of age, and the most appropriate treatment strategies remain a matter of debate...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2003.11.027

    authors: Chinot OL

    更新日期:2003-12-01 00:00:00

  • Single-agent oral etoposide for elderly small cell lung cancer patients.

    abstract::Among new patients with small cell lung cancer (SCLC), 20% to 25% are over 70 years of age and account for 8,000 cases annually in the United States. For such patients, intensive, aggressive, cytotoxic, combination chemotherapy is not often used because of its association with unacceptable morbidity and mortality rate...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Carney DN,Grogan L,Smit EF,Harford P,Berendsen HH,Postmus PE

    更新日期:1990-02-01 00:00:00

  • Diagnosis and treatment of metastatic disease to the liver.

    abstract::A number of cancers present with synchronous or metachronous hepatic metastases. Historically, many of these patients were considered unresectable and were treated with either systemic chemotherapy or supportive care. Today, a variety of options exist for the management of hepatic metastases. Newer agents for systemic...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2007.12.004

    authors: Arciero CA,Sigurdson ER

    更新日期:2008-04-01 00:00:00

  • Treatment of Waldenstrom's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone.

    abstract::To evaluate the activity of thalidomide in Waldenstrom's macroglobulinemia (WM), 20 patients were treated on a dose schedule that escalated from 200 mg/d to 600 mg/d. On an intention-to-treat basis, five (25%) patients achieved a partial response, which was noted within 3 months of treatment. Adverse effects were comm...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/sonc.2003.50079

    authors: Dimopoulos MA,Tsatalas C,Zomas A,Hamilos G,Panayiotidis P,Margaritis D,Matsouka C,Economopoulos T,Anagnostopoulos N

    更新日期:2003-04-01 00:00:00

  • Autoimmune complications of chronic lymphocytic leukemia.

    abstract::Autoimmune complications are common in chronic lymphocytic leukemia (CLL), occurring in up to a quarter of all patients during the course of the illness. By far the most common manifestation is autoimmune hemolytic anemia (AIHA), followed by immune thrombocytopenia (ITP). It is not true to say that autoimmunity is con...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2006.01.011

    authors: Hamblin TJ

    更新日期:2006-04-01 00:00:00

  • Improving patient care through molecular diagnostics.

    abstract::Traditional cancer diagnostic techniques include assessment of histologic appearance, identification of specific tumor subtypes, tumor grading, assessment of lymph node status, and presence of metastasis. These are useful for initial evaluation, but are limited in their ability to predict response to treatment and/or ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2004.07.017

    authors: Perez EA,Pusztai L,Van de Vijver M

    更新日期:2004-10-01 00:00:00

  • The National Cancer Institute and Department of Veterans Affairs Interagency Group to Accelerate Trials Enrollment (NAVIGATE): A federal collaboration to improve cancer care.

    abstract::Cancer clinical trials represent an important option for patients with a diagnosis of cancer and the clinician-investigators involved in their care who seek options for their disease. For all who are impacted by cancer, these studies offer opportunities for greater learning. Conducting these important studies involves...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2019.09.005

    authors: Schiller SJ,Shannon C,Brophy MT,Denicoff AM,Good MJ,Prindiville SA,Huang GD

    更新日期:2019-01-01 00:00:00

  • Advances in the biology of multiple myeloma: therapeutic applications.

    abstract::Recent advances in the biology of multiple myeloma cell growth and survival have suggested new avenues for treatment and potential cure of this disease. Adhesion molecules on the myeloma cell surface mediate their localization in the bone marrow via binding to extracellular matrix proteins and stromal cells. Stromal c...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Anderson K

    更新日期:1999-10-01 00:00:00

  • Incorporating genomics into the cancer clinical trial process.

    abstract::The effectiveness of current chemotherapeutic approaches for the treatment of solid tumors has reached a near plateau, suggesting we are nearing the limit of cytoreduction. It is hypothesized that this may be due to "subset effect," and that drugs administered according to responses predicted for particular subgroups ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1016/s0093-7754(01)90123-x

    authors: Paik S

    更新日期:2001-06-01 00:00:00

  • Phase II study of lomustine, cytarabine, mitoxantrone, and prednisone (CAMP) combination chemotherapy for doxorubicin-resistant intermediate- and high-grade malignant non-Hodgkin's lymphoma.

    abstract::A phase II study was conducted to evaluate the efficacy and toxicity of lomustine, cytarabine, mitoxantrone and prednisone (CAMP) chemotherapy in doxorubicin-resistant intermediate- and high-grade malignant non-Hodgkin's lymphomas (NHL). Among 30 patients, the complete remission rate was 27% (duration: 10, 16, 22, 35,...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Ruit JB,Löwenberg B,Hagenbeek A,Verhoef GE,Wielenga JJ,Michiels J,Sizoo W

    更新日期:1990-12-01 00:00:00

  • Efficacy of endoscopic variceal ligation for bleeding esophageal varices in patients with tumor thrombus of the portal vein trunk (Vp3) associated with hepatocellular carcinoma.

    abstract::We studied the efficacy of endoscopic variceal ligation (EVL) in 16 patients with tumor thrombus of the portal vein trunk (Vp3) associated with hepatocellular carcinoma. The average (+/-SD) number of O rings used was 9.0 +/- 5.0 for the esophageal varices (n = 7) and 16.4 +/- 4.5 for the esophagogastric varices (n = 9...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Kokubu S,Matsumoto Y,Murakami M,Shibata H,Saigenji K

    更新日期:1997-04-01 00:00:00

  • Monoclonal antibodies for the prevention and treatment of graft-versus-host disease.

    abstract::Acute and chronic graft-versus-host disease (GvHD) remain major obstacles to successful allogeneic hematopoietic stem cell transplantation, contributing substantially to morbidity and non-relapse mortality. Better understanding of the immunopathophysiology of GvHD has identified a number of targets for intervention. A...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1016/s0093-7754(03)00250-1

    authors: Bruner RJ,Farag SS

    更新日期:2003-08-01 00:00:00

  • Third-line salvage chemotherapy in Hodgkin's disease.

    abstract::CEP (CCNU, etoposide, and prednimustine) was tested as third-line chemotherapy in 40 patients resistant to both MOPP and ABVD. The observed response rate (complete remission, 35%, and partial remission, 25%) is encouraging. Treatment was generally well tolerated and all acute side effects were reversible. ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Bonadonna G,Viviani S,Valagussa P,Bonfante V,Santoro A

    更新日期:1985-03-01 00:00:00

  • Colon cancer in older adults.

    abstract::Colorectal cancer (CRC) is a common malignancy in the elderly. Randomized trials have demonstrated that adjuvant and palliative chemotherapy for CRC improves survival and quality of life. Unfortunately, there is a lack of evidence-based data about elderly patients to guide decisions regarding therapy. Clinical trials ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2008.08.004

    authors: Raftery L,Sanoff HK,Goldberg R

    更新日期:2008-12-01 00:00:00

  • Metastatic neuroendocrine tumors of the gastrointestinal tract and pancreas: A surgeon's plea to centering attention on the liver.

    abstract::Over 50% of patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) have stage IV disease at presentation and the most likely organ to be affected by metastases is the liver. Hepatic involvement and hepatic tumor burden is a key prognostic factor affecting survival of these patients and 80% eventually di...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2018.07.002

    authors: Keutgen XM,Schadde E,Pommier RF,Halfdanarson TR,Howe JR,Kebebew E

    更新日期:2018-08-01 00:00:00

  • Maintaining bone health in prostate cancer throughout the disease continuum.

    abstract::Prostate cancer (PC) is the most prevalent malignancy in men, with 604,506 new cases diagnosed yearly worldwide. Maintaining bone health is important during all stages of PC, including patients who experience bone loss from androgen-deprivation therapy and patients who develop bone metastases. Patients with bone metas...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2010.06.007

    authors: Saad F,Eastham J

    更新日期:2010-06-01 00:00:00